相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy
Jose Batista da Costa et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2022)
CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer
Moran Yang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
D. J. McGrail et al.
ANNALS OF ONCOLOGY (2021)
Tumor-infiltrating lymphocytes in the immunotherapy era
Sterre T. Paijens et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma
Liang-qing Dong et al.
JOURNAL OF HEPATOLOGY (2020)
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Daixi Ren et al.
MOLECULAR CANCER (2020)
B cells are associated with survival and immunotherapy response in sarcoma
Florent Petitprez et al.
NATURE (2020)
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
Rita Cabrita et al.
NATURE (2020)
B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink et al.
NATURE (2020)
Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics
Hugo Arasanz et al.
CANCERS (2020)
Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
Victor C. Kok
FRONTIERS IN ONCOLOGY (2020)
Tertiary lymphoid structures in cancer - considerations for patient prognosis
Luis Munoz-Erazo et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Mechanisms of resistance to T cell-based immunotherapy in head and neck cancer
Maxwell Y. Lee et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2020)
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer
Sumit K. Subudhi et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
Jenny H. Lee et al.
NATURE COMMUNICATIONS (2020)
Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy
Muhammad Zaeem Noman et al.
SCIENCE ADVANCES (2020)
Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
Hongjing Zang et al.
FRONTIERS IN ONCOLOGY (2020)
Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes
Joshua J. Meeks et al.
NATURE REVIEWS UROLOGY (2020)
Mechanisms of Cancer Resistance to Immunotherapy
Rilan Bai et al.
FRONTIERS IN ONCOLOGY (2020)
Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy
Lina Such et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker
Zhengyi Wang et al.
CANCER MEDICINE (2020)
Hyperprogression: A novel response pattern under immunotherapy
Xue-jiao Han et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2020)
Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy
Anthony B. Rodriguez et al.
CANCER IMMUNOLOGY RESEARCH (2020)
B cells, plasma cells and antibody repertoires in the tumour microenvironment
George Sharonov et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants
Joshua I. Warrick et al.
EUROPEAN UROLOGY (2019)
Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients
Corentin Richard et al.
CLINICAL CANCER RESEARCH (2019)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
Giuseppe Lo Russo et al.
CLINICAL CANCER RESEARCH (2019)
Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome
Federico Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy
Maxim Shevtsov et al.
FRONTIERS IN ONCOLOGY (2019)
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
A. B. Schrock et al.
ANNALS OF ONCOLOGY (2019)
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
C. G. Kim et al.
ANNALS OF ONCOLOGY (2019)
The Intersection between Tumor Angiogenesis and Immune Suppression
Osama E. Rahma et al.
CLINICAL CANCER RESEARCH (2019)
Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma
Ting Yan et al.
NATURE COMMUNICATIONS (2019)
Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer
Matteo Ligorio et al.
CELL (2019)
Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses
Chikara Ohyama et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2019)
Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients
Seon Ah Lim et al.
FRONTIERS IN IMMUNOLOGY (2019)
B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma
Johannes Griss et al.
NATURE COMMUNICATIONS (2019)
Mechanisms regulating PD-L1 expression on tumor and immune cells
Shuming Chen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma (vol 175, 998.e1 , 2018)
Moshe Sade-Feldman et al.
CELL (2019)
Expression of cancer-testis antigens in esophageal cancer and their progress in immunotherapy
Yujie Zhang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Immunotherapeutic advances in gastrointestinal malignancies
Devika Rao et al.
NPJ PRECISION ONCOLOGY (2019)
Tertiary lymphoid structures in the era of cancer immunotherapy
Catherine Sautes-Fridman et al.
NATURE REVIEWS CANCER (2019)
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell et al.
SCIENCE (2018)
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan et al.
SCIENCE (2018)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape
Francisco Perea et al.
ONCOTARGET (2018)
Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients
Xiaofang Xing et al.
ONCOIMMUNOLOGY (2018)
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
T. R. Cottrell et al.
ANNALS OF ONCOLOGY (2018)
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Vancheswaran Gopalakrishnan et al.
CANCER CELL (2018)
Hyperprogression as a distinct outcome after immunotherapy
J. Fuentes-Antras et al.
CANCER TREATMENT REVIEWS (2018)
Tumor-derived lactate induces M2 macrophage polarization via the activation of the ERK/STAT3 signaling pathway in breast cancer
Xianmin Mu et al.
CELL CYCLE (2018)
Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets
Stephan Lang et al.
CLINICAL CANCER RESEARCH (2018)
The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses
Natalia Aptsiauri et al.
CURRENT OPINION IN IMMUNOLOGY (2018)
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures
Anne M. Stowman et al.
MELANOMA RESEARCH (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment
Elisa Peranzoni et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Vyara Matson et al.
SCIENCE (2018)
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Laurence Zitvogel et al.
SCIENCE (2018)
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Rebekka Weber et al.
FRONTIERS IN IMMUNOLOGY (2018)
Precision medicine and bladder cancer heterogeneity
Guofeng Ma et al.
BULLETIN DU CANCER (2018)
High response rate to PD-1 blockade in desmoplastic melanomas
Zeynep Eroglu et al.
NATURE (2018)
EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
Li Wang et al.
NATURE COMMUNICATIONS (2018)
Immuno-Oncology: Emerging Targets and Combination Therapies
Henry T. Marshall et al.
FRONTIERS IN ONCOLOGY (2018)
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N. Amaria et al.
NATURE MEDICINE (2018)
Hyperprogressive disease: recognizing a novel pattern to improve patient management
Stephane Champiat et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The Clinical Impact of the Genomic Landscape of Mismatch Repair-Deficient Cancers
Giovanni Germano et al.
CANCER DISCOVERY (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma
Karina Silina et al.
CANCER RESEARCH (2018)
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
David A. Fabrizio et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies
Shumei Kato et al.
JCO PRECISION ONCOLOGY (2018)
Multilayered Omics-Based Analysis of a Head and Neck Cancer Model of Cisplatin Resistance Reveals Intratumoral Heterogeneity and Treatment-Induced Clonal Selection
Franziska Niehr et al.
CLINICAL CANCER RESEARCH (2018)
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Stephane Champiat et al.
CLINICAL CANCER RESEARCH (2017)
The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration
Francisco Perea et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages
Hideyuki Takahashi et al.
ONCOTARGET (2017)
Role of chromosomal instability in cancer progression
Sarah E. McClelland
ENDOCRINE-RELATED CANCER (2017)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter et al.
LANCET (2017)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang et al.
NATURE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation
Elizabeth Allen et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer
David Liu et al.
NATURE COMMUNICATIONS (2017)
Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer
In Hye Song et al.
CANCER RESEARCH AND TREATMENT (2017)
Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor immunity, immunosuppression, or Bystander Sentinels in Disease?
Emily Jayne Colbeck et al.
FRONTIERS IN IMMUNOLOGY (2017)
Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients
Arthur E. Frankel et al.
NEOPLASIA (2017)
Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors
Martin H. Pedersen et al.
ONCOIMMUNOLOGY (2017)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
Nicholas McGranahan et al.
CELL (2017)
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
Shumei Kato et al.
CLINICAL CANCER RESEARCH (2017)
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
E. Saada-Bouzid et al.
ANNALS OF ONCOLOGY (2017)
Bench to bedside: NK cells and control of metastasis
Yelena Krasnova et al.
CLINICAL IMMUNOLOGY (2017)
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
Nicholas McGranahan et al.
CELL (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
T cells for viral infections after allogeneic hematopoietic stem cell transplant
Catherine M. Bollard et al.
BLOOD (2016)
Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma
Philippe Lamy et al.
CANCER RESEARCH (2016)
Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis
Long-Yun Ye et al.
CANCER RESEARCH (2016)
Microbiome and Anticancer Immunosurveillance
Laurence Zitvogel et al.
CELL (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Microsatellite Instability as a Biomarker for PD-1 Blockade
Jonathan C. Dudley et al.
CLINICAL CANCER RESEARCH (2016)
Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers
Marie-Caroline Dieu-Nosjean et al.
IMMUNOLOGICAL REVIEWS (2016)
The impact of hypoxia on tumor-associated macrophages
Anne-Theres Henze et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment
Koichi Sakakura et al.
LABORATORY INVESTIGATION (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer
Ruth J. Davis et al.
ORAL ONCOLOGY (2016)
ENHANCED INNATE INFLAMMATION INDUCED BY ANTI-BTLA ANTIBODY IN DUAL INSULT MODEL OF HEMORRHAGIC SHOCK/SEPSIS
Tingting Cheng et al.
SHOCK (2016)
Prognostic value of tumor infiltrating NK cells and macrophages in stage II plus III esophageal cancer patients
Bin Xu et al.
ONCOTARGET (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
A Case of Non-Small Cell Lung Cancer with Possible Disease Flare on Nivolumab Treatment
Shotaro Chubachi et al.
CASE REPORTS IN ONCOLOGICAL MEDICINE (2016)
Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab
Hee Jin Lee et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2015)
Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses
Nikhil S. Joshi et al.
IMMUNITY (2015)
Objective Measurement and Clinical Significance of TILs in Non-Small Cell Lung Cancer
Kurt A. Schalper et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
Ayelet Sivan et al.
SCIENCE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vetizou et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Objective Measurement and Clinical Significance of TILs in Non-Small Cell Lung Cancer
Kurt A. Schalper et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Cellular Mechanisms Underlying Intertumoral Heterogeneity
Kate D. Sutherland et al.
TRENDS IN CANCER (2015)
Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer
Claire Germain et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis
Z. Mei et al.
BRITISH JOURNAL OF CANCER (2014)
CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
Yu Zhu et al.
CANCER RESEARCH (2014)
Occurrence of Tertiary Lymphoid Tissue Is Associated with T-Cell Infiltration and Predicts Better Prognosis in Early-Stage Colorectal Cancers
Giuseppe Di Caro et al.
CLINICAL CANCER RESEARCH (2014)
Tumor-Associated Macrophages: From Mechanisms to Therapy
Roy Noy et al.
IMMUNITY (2014)
Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways
Patrick L. Raber et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins
Catherine M. Bollard et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Adoptive T-cell Transfer and Chemotherapy in the First-line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma
Whay-Kuang Chia et al.
MOLECULAR THERAPY (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
Jianjun Zhang et al.
SCIENCE (2014)
Tertiary lymphoid structures in cancer and beyond
Marie-Caroline Dieu-Nosjean et al.
TRENDS IN IMMUNOLOGY (2014)
Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer
N. Chaput et al.
BRITISH JOURNAL OF CANCER (2013)
CXCR2-Expressing Myeloid-Derived Suppressor Cells Are Essential to Promote Colitis-Associated Tumorigenesis
Hiroshi Katoh et al.
CANCER CELL (2013)
Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
Dan A. Landau et al.
CELL (2013)
Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin
Romain Remark et al.
CLINICAL CANCER RESEARCH (2013)
Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis
Jeremy D. Waight et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma
Nadia Lago Costa et al.
ORAL ONCOLOGY (2013)
Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Christine Feig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer
Robert Wesolowski et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2013)
T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results
S. Secondino et al.
ANNALS OF ONCOLOGY (2012)
Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors
Helene Salmon et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
Jane L. Messina et al.
SCIENTIFIC REPORTS (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Prognostic impact of B-cell density in cutaneous melanoma
Andrea Ladanyi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Anti-TIM3 Antibody Promotes T Cell IFN-γ-Mediated Antitumor Immunity and Suppresses Established Tumors
Shin Foong Ngiow et al.
CANCER RESEARCH (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Tumor Cells and Tumor-Associated Macrophages: Secreted Proteins as Potential Targets for Therapy
Marc Baay et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2011)
Immune defence against EBV and EBV-associated disease
Heather M. Long et al.
CURRENT OPINION IN IMMUNOLOGY (2011)
Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors
Isabel Maleno et al.
IMMUNOGENETICS (2011)
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Omid Hamid et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Tertiary Intratumor Lymphoid Tissue in Colo-Rectal Cancer
Francesca Bergomas et al.
Cancers (2011)
Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes
Kiavash Movahedi et al.
CANCER RESEARCH (2010)
Effector and memory CD8+ T cell differentiation: toward a molecular understanding of fate determination
Gabrielle T. Belz et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
Biomolecular Network Reconstruction Identifies T-Cell Homing Factors Associated With Survival in Colorectal Cancer
Bernhard Mlecnik et al.
GASTROENTEROLOGY (2010)
Immune evasion of microsatellite unstable colorectal cancers
Matthias Kloor et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma
Chrystal U. Louis et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Induction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21
Jacqueline D. Shields et al.
SCIENCE (2010)
Cancer/testis (CT) antigens: Potential targets for immunotherapy
Otavia L. Caballero et al.
CANCER SCIENCE (2009)
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
Dong-Ming Kuang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens
Luiz Gonzaga Almeida et al.
NUCLEIC ACIDS RESEARCH (2009)
Migration of dendritic cell subsets and their precursors
Gwendalyn J. Randolph et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer
Yoshiki Mizukami et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures
Marie-Caroline Dieu-Nosjean et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients
Andrea Anichini et al.
CANCER RESEARCH (2006)
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
I Kryczek et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers
M Kloor et al.
CANCER RESEARCH (2005)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
Chemokines as regulators of T cell differentiation
SA Luther et al.
NATURE IMMUNOLOGY (2001)
分享论文
